Robeco Institutional Asset Management B.V. Raises Stock Holdings in Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

Robeco Institutional Asset Management B.V. lifted its position in Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 20.3% during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 201,304 shares of the specialty pharmaceutical company's stock after acquiring an additional 33,948 shares during the period. Robeco Institutional Asset Management B.V. owned 0.33% of Jazz Pharmaceuticals worth $24,791,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other hedge funds have also recently added to or reduced their stakes in JAZZ. CWA Asset Management Group LLC acquired a new stake in shares of Jazz Pharmaceuticals in the third quarter valued at about $3,197,000. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its holdings in shares of Jazz Pharmaceuticals by 135.3% during the 3rd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 174,078 shares of the specialty pharmaceutical company's stock worth $19,394,000 after purchasing an additional 100,112 shares during the last quarter. Centre Asset Management LLC purchased a new stake in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $9,335,000. Pacer Advisors Inc. increased its holdings in shares of Jazz Pharmaceuticals by 15.3% in the third quarter. Pacer Advisors Inc. now owns 2,099,378 shares of the specialty pharmaceutical company's stock valued at $233,892,000 after purchasing an additional 278,465 shares during the last quarter. Finally, Franklin Resources Inc. lifted its position in Jazz Pharmaceuticals by 4.6% during the third quarter. Franklin Resources Inc. now owns 1,118,688 shares of the specialty pharmaceutical company's stock worth $124,208,000 after buying an additional 48,708 shares in the last quarter. 89.14% of the stock is owned by institutional investors and hedge funds.

Jazz Pharmaceuticals Stock Down 2.0 %

Shares of JAZZ traded down $2.46 during midday trading on Monday, hitting $121.92. The company had a trading volume of 205,914 shares, compared to its average volume of 492,674. The company's 50-day simple moving average is $122.69 and its 200-day simple moving average is $116.10. The firm has a market capitalization of $7.37 billion, a P/E ratio of 17.25, a P/E/G ratio of 0.90 and a beta of 0.56. Jazz Pharmaceuticals plc has a 1 year low of $99.06 and a 1 year high of $134.17. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on JAZZ shares. Morgan Stanley raised shares of Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and boosted their price target for the company from $140.00 to $175.00 in a research report on Thursday, December 12th. Needham & Company LLC restated a "buy" rating and set a $207.00 price target on shares of Jazz Pharmaceuticals in a report on Thursday, December 12th. HC Wainwright reiterated a "buy" rating and issued a $200.00 price objective on shares of Jazz Pharmaceuticals in a report on Friday, November 22nd. Royal Bank of Canada reissued an "outperform" rating and set a $179.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday, December 10th. Finally, Robert W. Baird lifted their target price on Jazz Pharmaceuticals from $154.00 to $162.00 and gave the company an "outperform" rating in a research report on Monday, November 18th. Two equities research analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the stock has an average rating of "Moderate Buy" and an average target price of $177.00.

Insider Activity at Jazz Pharmaceuticals

In other Jazz Pharmaceuticals news, CEO Bruce C. Cozadd sold 1,500 shares of the firm's stock in a transaction on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total transaction of $185,145.00. Following the transaction, the chief executive officer now directly owns 425,525 shares of the company's stock, valued at approximately $52,522,550.75. This trade represents a 0.35 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, EVP Neena M. Patil sold 3,700 shares of the company's stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $123.41, for a total value of $456,617.00. Following the sale, the executive vice president now directly owns 33,048 shares of the company's stock, valued at approximately $4,078,453.68. This represents a 10.07 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 7,253 shares of company stock valued at $890,594 over the last quarter. 4.20% of the stock is owned by insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.